Transce3nd’s Palisade Bio PALI Stock Holding History

Transce3nd’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$680	–	839
2025 Q2	$680	Buy	+1,000	New	+$716	﹤0.01%	1040

Other funds holding PALI

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $808M AUM 51.1% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Transce3nd's PALI Position: Q3 2025 in Review

Transce3nd sold out of Palisade Bio (PALI) in Q3 2025, closing a stake of 1,000 shares — an estimated $680 sold.

Transce3nd first reported a position in PALI in Q2 2025 and held it in 1 quarter. The position peaked at $680 in Q2 2025. 12 funds tracked by Wall St. Rank hold PALI as of Q3 2025.

Transce3nd reported no remaining Palisade Bio position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 1,000 Palisade Bio shares in Q3 2025, an estimated $680.
Transce3nd first reported a position in Palisade Bio in Q2 2025 and held it in 1 quarter.
Transce3nd's Palisade Bio position peaked at $680 in Q2 2025.
12 funds tracked by Wall St. Rank held Palisade Bio as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.